3-D model for lung cancer mimics the real thing

October 11, 2012
3-D model for lung cancer mimics the real thing

(Medical Xpress)—A new technique that allows scientists to grow lung cancer cells in three dimensions could accelerate discoveries for a type of cancer that has benefited little from scientific research over the last several decades.

The , created by researchers at The Methodist Hospital and the University of Texas MD Anderson Cancer Center, uses biological matter to form miniature lungs that mimic the structure and function of real lung cancer, after which human are added. Findings from the model's first tests were recently published in the journal .

"We found that the 3-D model we devised worked in most respects much better than 2-D models currently being used in lung cancer research," said Min Kim, M.D., the study's principal investigator. "New models for lung cancer research are crucial because current models frequently do not correlate with the findings of human trials. The challenge is creating a model that we can study that can accurately predict what will happen in patients with lung cancer."

aiding the understanding and treatment of lung cancer have been limited and slow relative to breast and , among others. In 1975, the five-year survival rate for patients diagnosed with lung cancer was 13 percent. In 2005 (the most recent year for which reliable data are available), that survival rate had only increased to 16 percent.

"The lack of progress in finding effective treatments for lung cancer may be due, in part, to the lack of an that mimics the biological processes that occur in patients with lung cancer," said Dhruva Mishra, Ph.D. the paper's first author.

The Methodist-MD Anderson model uses a rat lung "matrix," a framework created after the rat have been chemically removed. This translucent matrix is then infused with human lung derived either from a patient or from a cell line. The cells that stick to the matrix are allowed to grow in nutrient rich, oxygenated broth that moves into and out of the lung space.

The model was first described by Mishra and many of his PLOS One co-authors in an Annals of Thoracic Surgery paper in April 2012. The present PLOS One paper reports the first tests of the model comparing its performance to other non-animal models.

The 2-D model Mishra and colleagues used for comparison is the conventional, flat surface flask, the most commonly used system for cell culture. Cells grow along one of the flattened sides below a shallow broth of nutrients. This model is commonly used in lung cancer research.

Mishra and his co-authors found that unlike the 2-D model, their 3-D model allowed the lung cancer to form "nodules," something the cancer does naturally in living tissue. The nodules are believed to play a crucial role in the cancer's growth and metastasis. The 2-D model produced an unnaturally high number of cells if left alone, whereas cell growth in the 3-D model provided more realistic cell growth and programmed cell death. The 3-D model also coaxed meaningful growth with preserved vasculature for inflow of nutrients and cells after four and six days showed signs of interacting with each other (also a natural phenomenon). in the 2-D model simply grew haphazardly to fill spaces.

The 3-D model also produced more matrix metalloproteinases, a family of enzymes that researchers believe are required for lung cancer cell growth. Other important gene products, caspase-3 and ki-67, were also measured at higher levels in the 3-D model.

"Our lab is exploring this novel 3-D model for to better understand the mechanism behind cancer metastasis," Kim said.

Explore further: Study identifies gene critical to development and spread of lung cancer

Related Stories

Study identifies gene critical to development and spread of lung cancer

April 24, 2012
A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida. Their study suggests other forms of cancer may ...

First and only therapeutic drug for ALK-positive lung cancer approved

August 31, 2011
In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.